Drugs / raclopride
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03648892 | Sep 2018 → Mar 2022 | obesity disorder | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT05282277 Background | Apr 2022 → Dec 2026 expected | atypical depressive disorder, depressive disorder, psychotic disorder | University of North Carolina, Chapel Hill | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | raclopride | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03648892 ↗ |
| Route | Intravenous | “\[11C\]raclopride IV” NCT05282277 ↗ |